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Tuberculosis is a debilitating respiratory disease caused by the bacterial species 
Mycobacterium tuberculosis​, which acts by infecting the host’s macrophages and evading their 
immune responses. The purpose of the study was to determine if RAW 264.7 murine 
macrophage activity could be facilitated and intensified by stimulation with LAM from ​M. 
smegmatis​. Stimulation with bacterial LAM, and lipopolysaccharide (LPS) as a positive control, 
yields functional endpoints: nitric oxide (NO) production measured by nitrites (NO​2​) in the 
culture supernatant and expression of proteins, such as tumor necrosis factor-α and inducible 
nitric oxide synthase (iNOS). RAW 264.7 cells were stimulated dose-responsively with LAM at 
concentrations of 1-1000 ng/mL. Use of 100 ng/mL LPS served as a positive control. Nitrite, an 
indirect product of the NO inflammatory response, was measured by the Greiss reaction and total 
protein was collected from the cells for western blotting to quantify iNOS. Preliminary results in 
experiment one showed that LAM NO production was minimally noticeable in the 1000 ng/mL 
dose and was still substantially lower than the LPS control when evaluated by the Greiss Assay. 
Experiments two and three were conducted with higher doses of Lam, 3000 ng/mL and 5000 
ng/mL and showed an increased response. The nitrite concentration reached by both these LAM 
treatments still did not reach that of 100 ng/mL LPS. This result suggests that the pattern 
recognition difference between Toll-like receptor-2 (TLR-2) for LAM and Toll-like receptor-4 





While the COVID-19 outbreak far overshadowed many significant anniversaries in the 
early part of 2020, the CDC annually recognizes March 24​th​ as World TB Day. It marks the 
discovery of ​Mycobacterium tuberculosis​, the bacterial species that causes the disease, by Dr. 
Robert Koch in 1882 (CDC 2016). This anniversary, though not a celebration, is a day for 
recognition of the infection that has been wreaking havoc on human populations for thousands of 
years. Tuberculosis (TB), historically referred to as scrofula, the White Plague, and consumption, 
is a respiratory disease and is transmittable from person to person via droplets from the sneezes 
or coughs of an actively infected individual (Tuberculosis 2018). The 2019 World Health 
Organization (WHO) TB report indicated that in 2018, there was a global estimate of 10 million 
people diagnosed with the illness and nearly 1.5 million deaths (WHO 2019). Caused by 
Mycobacterium tuberculosis ​(​Mtb​), this disease has evolved to be multi-drug resistant (MDR) 
and requires a grueling six-month course of antibiotics to cure. Health and research professionals 
often wonder how the ancient bacterial illness can still be so difficult to eradicate. The durability 
of the pathogen can be attributed to the presence of persister cells, a dormant variant of a normal 
cell that is slow growing and resistant to even high levels of antibiotics (Lewis 2010). These cells 
likely evolved as an adaptation from competing with the human immune system (Lougheed 
2017). Since these cells make the infection particularly impervious, it is crucial to research and 
develop techniques that may improve the treatment process to more efficiently and effectively 
eliminate TB. This requires a thorough understanding of the pathways in which TB infects its 
host and how those mechanisms may be manipulated to weaken the bacteria. 
In 2018 the WHO estimated that nearly one third of the world’s population carries 
tuberculosis and that ten percent of those will acquire the infection, becoming a vector of the 
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disease. While these numbers seem underwhelming, an estimated 10.4 million new cases, 1.7 
million being fatal, arose in 2016 (Tuberculosis 2018). The disease, caused by ​Mtb ​bacterial 
infection, often manifests as a respiratory infection but can also cause extrapulmonary disease to 
organ systems such as in lymph node TB, skeletal TB, and genitourinary TB (Fanning 1999). 
The disease is particularly virulent in those who become immunocompromised through age, 
another disease, or otherwise. In addition, many individuals with the infection have a latent form 
that may take years to unexpectedly activate. These factors lead to a bacterial contagion that 
aggressively eludes the human immune system and many modern treatment attempts. 
Pathogens have individual characteristics that determine their virulence by impacting 
their hosts in unique ways. The distinguishing feature that heavily contributes to resilience is 
their defensive outer layer. The cell envelope of Gram-positive bacteria is composed of an inner 
membrane, phospholipid bilayer, surrounded by a thick layer of peptidoglycan that makes up the 
rigid cell wall (Salton and Kim 1996). In contrast, Gram-negative bacteria have a very thin layer 
of peptidoglycan separated from the inner membrane by periplasm and surrounded by another 
phospholipid bilayer, the outer membrane (Fig. 1). Gram-negative bacteria also contain 
lipopolysaccharide (LPS). Embedded in the outer membrane, the molecule activates the host 
immune system and acts as an endotoxin when the bacterial cell is attacked. Mycobacteria often 
resemble Gram-negative bacteria given the complexity of the cellular envelope; however, they 
possess a capsule instead of an outer membrane and some of their internal components are 
characteristic of only mycobacteria (Fig. 2). Lipomannan (LM) and lipoarabinomannan (LAM) 
are examples of essential compounds of the mycobacterial cell envelope, though their exact 




Figure 1: Comparison of the Gram-negative (left) and Gram-positive (right) cell envelopes. 
Gram-negative cells contain an inner membrane, a periplasmic space, a thin peptidoglycan layer, 
dense lipoproteins, and an outer membrane. Gram-positive bacteria contain an inner membrane 




Figure 2: Diagram of a mycobacterial cell envelope. Layer from inside to out are inner 
membrane, peptidoglycan and arabinoglycan, mycolic acids and extractable lipids, and a capsule. 





Various proteins and polysaccharides contribute to the pathogenicity of mycobacterial species 
and especially serve as a physical barrier to host defensive processes. 
When the human immune system comes into contact with foreign particles, there are a 
number of primary responders that identify whether or not the particle is a threat. When the 
innate immune system recognizes signature proteins in pathogens, such as LPS or LAM, the 
attack and elimination of the intruder begins. The macrophage is an important phagocyte, a cell 
type that engulfs foreign particles, and an initial responder in the innate immune system. 
Invaders are taken up as the cell membrane of the macrophage reaches around the particle, 
forming a pocket called a phagosome. Under normal operation, this phagosome containing 
harmful bacteria would be fused with a lysosome, releasing chemicals to destroy the bacteria 
(Slonczewski and Foster 2017). One of these chemicals is nitric oxide (NO), released by a 
protein called inducible nitric oxide synthase (iNOS). NO is responsible for killing many 
intracellular organisms, including some mycobacteria (Park et al. 2000). Though different 
species of microbes are vastly diverse in structure, there are a few common structural 
components such as LPS in Gram-negative bacteria, peptidoglycan in Gram-positive bacteria, 
and LAM in mycobacteria (Takeuchi and Akira 2001). These fundamental units activate the 
host’s innate immune system and facilitate response to the pathogen. 
Macrophages have many types of receptors through which mycobacterial particles bind, 
inducing the maturation of the phagosome (Daffé and Reyrat 2008). One example is the mannose 
receptor (MR). When TB comes in contact with the human immune system, mannose-capped 
LAM interacts with the MR on the surface of the macrophage, initiating the phagocytosis of ​Mtb​. 
This specific activation of the MR from ​Mtb​ negatively impacts the development of the 
phagosome, reducing the capacity for phagolysosomal fusion (Daffé and Reyrat 2008). Toll-like 
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receptors (TLRs) also exist on the surface of phagocytic cells and upon reception of a recognized 
molecule, release pro-inflammatory cytokines. These substances, such as interleukin-1 (IL-1), 
interleukin-12 (IL-12), and tumor necrosis factor-α (TNF-α) mediate the inflammatory process 
and aid other immunological cells in their response to the invader (Dinarello 2000). LAM 
modulates the host immune system by preventing the release of pro-inflammatory cytokines 
IL-12 and TNF-α (Daffé and Reyrat 2008). The molecules aid leukocytes in adhering to 
endothelial cells before emigrating to tackle the infection (Dinarello 2000). Without these 
signaling molecules, other immune cells are not alerted to the presence of the disease and the 
immune response does not achieve maximum efficiency. 
It is still largely unknown how ​Mtb​ evades the cytocidal properties of macrophages. In 
order to effectively target the disease, it is crucial to understand the pathway it takes to infect its 
host. While TLR-4 is responsible for recognition of LPS and the stimulation of iNOS to produce 
NO, there is evidence that LAM interacts with macrophages through TLR-2 (Takeuchi and Akira 
2001). This difference could be responsible for the ability of ​Mtb​ to resist lysosomal degradation 
inside the phagocyte. One potential research avenue is to investigate the role of TLR-2 as ​Mtb 
evades the immune system. A second line of study is needed for better understanding of the 
stimulatory effects of mycobacterial LAM on macrophages. Previous research indicates that 
there are significant differences in the levels of response triggered by treatment of macrophages 
with LPS and LAM. In order to narrow-down the potential causes for this discrepancy, 
experiments that measure other inflammatory products must be explored. 
Tuberculosis is a Bio-Safety Level 3 pathogen and it requires extreme caution and a 
negative airflow laboratory when cultured. Given the elevated risk, LAM from ​Mycobacterium 
smegmatis​ is utilized as a non-pathogenic model and substitute for LAM from ​Mtb​. 
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Lipoarabinomannan from ​M. smegmatis​ is also accessible and practical for use in the lab. The 
LAM found in both ​Mtb ​and ​M. smegmatis​ is identical, except for capping variations that can 
occur in some strains of each species (Fig. 3) (Mishra et al. 2011). Without the capping 
molecules, the base structure for LAM of ​Mtb ​and ​M. smegmatis​ is identical. 
An inevitable constraint encountered in all medical research is the ethics of testing and 
validating new technologies. In order to avoid breaching medical ethics, non-human animal and 
cellular models are often developed to take the place of what would otherwise need to be 
human-derived. A murine macrophage model has been developed as one standard for research on 
these monocytes. The RAW 264 cell line was established from tumors in mice with Abelson 
leukemia virus (Raschke et al. 1978). The strain of macrophages is immortal, meaning it can be 
maintained for an extended period of time by regularly transferring a sample of the cells to a new 
flask and replenishing nutrients. This enables the experimenters to perform multiple experiments 
on one original batch of cells. Specifically, the RAW 264.7 cell line has a well-established 
response to LPS and can be used to observe production of NO, iNOS, and TNF-α in response to 
bacterial infection. While human macrophages do not produce identical levels of NO, the murine 




Figure 3: Structures of lipoarabinomannan and related glycoconjugates from the cell envelope of 
M. tuberculosis​, ​M. smegmatis​, and ​C. glutamicum​. The black boxes indicate LAM variations in 
both ​M. tuberculosis ​(left) and ​M. smegmatis ​(right), identical except for their capping. The 
LAM found in ​M. tuberculosis ​is capped with mannose residues, making it Man-LAM. The 
LAM found in ​M. smegmatis​ is capped with phosphate (gray) and inositol (blue), making if 
PI-LAM (Adapted from Mishra et al. 2011). 
 
The purpose of the study was to determine if RAW 264.7 murine macrophage activity 
could be facilitated and intensified by stimulation with LAM from ​M. smegmatis​. The 
downstream effect is the production of inflammatory mediators, including NO and cytokines. 
The product observed was NO, quantified with the Greiss assay which measures the stable 
intermediate, nitrite. The expected results would indicate a dose-related response after 
stimulation with LAM from ​M. smegmatis​. These levels were compared to the stimulation with 
LPS from ​E. coli​, the positive control. If there is a significant difference in response levels from 
the two compounds, the signal transduction pathways connected to Toll-like receptors for both 
bacterial components will be explored in an attempt to identify the best method for measuring 
macrophage response to LAM.  
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MATERIALS AND METHODS 
Cell Culture 
The RAW 264.7 cells (ATCC; Manassas, VA) were cultured in DMEM complete, a 
solution containing DMEM with 4.5 g/L glucose and L-glutamine (Lonza/BioWhittaker; 
Walkersville, MD), 10% fetal bovine serum (Atlanta Biological, Lot#K13145; Flowery Branch, 
GA), NaCO​3 ​(Sigma-Aldrich; St. Louis, MO), and penicillin/streptomycin (Sigma-Aldrich; St. 
Louis, MO). Cells were grown in 25 cm​2​ plastic flasks (CellTreat Scientific Products; Pepperell, 
MA) in an incubator (Shel Labs; Cornelius, OR) under the following conditions: 37°C, 5% CO​2​, 
and 90% humidity. Passage of the cells occurred every 4 days by scraping and transferring to 5 
mL of fresh media, maintaining a 1:20 cells to media ratio. The cells were stained with trypan 
blue and counted using a hemocytometer prior to each experiment in order to determine viability 
and cells per unit volume. 
LAM Treatment 
All experiments were performed between passes 5-20. In order to achieve a cell 
concentration of 0.8x10​6​ cells/mL, the appropriate volume of DMEM complete was added. A 
24-well tissue culture plate (Costar Corning; Kennebunk, ME) was used and 500 μL of the cell 
suspension was aliquoted to each well, yielding 4.0x10​5​ cells/well. After 12-16 hours of 
incubation, the wells were washed twice with 500 μL DMEM. The LAM utilized in this 
experiment was derived from ​Mycobacterium smegmatis​ (InvivoGen; San Diego, CA) at a stock 
concentration of 0.33 μg/mL. The LPS used was from ​Escherichia coli​, strain O55:B5 
(Sigma-Aldrich; St. Louis, MO) and the stock concentration was 5 mg/mL.​ ​Treatment with LAM 
occurred in the following concentrations: 0 ng/mL, 1 ng/mL, 10 ng/mL, 100 ng/mL, 1000 ng/mL 
and 100 ng/mL LPS as a positive control. In order to maximize LAM response, an alternative 
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dose response experiment was executed at the following LAM concentrations: 0 ng/mL, 100 
ng/mL, 1000 ng/mL, 3000 ng/mL, 5000 ng/mL, and 100 ng/mL LPS. All 24-well plates were 
incubated 24 hours following the addition of LAM or LPS for the induction of NO.  
Greiss Assay 
Sodium nitrite was used to create a standard curve of 1 μM to 125 μM nitrite along two 
duplicate rows in a 96-well plate. The treated 24-well plate was retrieved from the incubator and 
centrifuged for 2 minutes at 1000 rpm to remove any cell material from the supernatant. The 
layout of each 24-well plate was replicated by transferring 50 μL of supernatant from each 
treated well. The Greiss reagent was comprised of a 1:1 mixture of 1% sulfanilamide in 2.5% 
phosphoric acid and 0.1% napthylethylenediamene dihydrochloride in 2.5% phosphoric acid. 
Each well received 100 μL of the Greiss reagent. After about five minutes, a microplate reader 
(BioTek Epoch with Gen 5 software, BioTek Instruments Inc.; Winooski, VT) recorded the 
absorbance of each well at 550 nm and the results were exported to a spreadsheet. The standard 
curve from sodium nitrite was used to determine the nitrite concentrations of experimental 
samples. Each treatment was done in four replicate wells and these values were averaged. 
Protein Isolation 
A 200 μL sample was removed from each sample well of the 24-well plate to be frozen 
(at -80°C) for future cytokine analysis. Then total protein was collected from each well to be 
used for western blotting. The RIPA mixture was made using 3 mL RIPA buffer (with triton 
X-100; Boston Bioproducts; Worcester, MA), 15 μL bovine lung Aprotinin (Sigma-Aldrich; St. 
Louis, Missouri), 15 μL Sigma P8340 protease inhibitor cocktail (Sigma-Aldrich; St. Louis, 
Missouri), and 6 μL 0.5M EDTA (Sigma-Aldrich; St. Louis, Missouri). Each well was washed 
twice with 500 μL PBS (calcium/magnesium-free phosphate buffered saline; Sigma-Aldrich; St. 
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Louis, Missouri) and received 100 μL of the RIPA mixture. After five minutes, a pipette tip was 
used to scrape and triturate each well. All four wells containing the same treatment concentration 
were consolidated into an individual microcentrifuge tube (USA Scientific; Orlando, FL), all of 
which were stored in the -80°C freezer. 
Bradford Assay 
A protein standard curve was created using five stepwise dilutions from 2mg/mL Bovine 
Serum Albumin (BSA; Sigma-Aldrich; St. Louis, Missouri). The dilutions of 5, 10, 20, 40, and 
80 μg BSA were placed in a 96-well plate in 200 μL aliquots across the top row. In the second 
row, 1 μL samples from the isolated RAW 264.7 proteins were inserted into 159 μL diH​2​O. Each 
well containing sample received 40 μL of Bradford reagent (BioRad Laboratories; Hercules, 
CA). The liquids were triturated to ensure thorough color dispersion. Trituration was performed 
to ensure the Coomassie Blue interacted and bonded with the proteins. The plate was inserted 
into the BioTek microplate reader and absorbance was measured at 595 nm. The standard curve 
from BSA was used to determine the protein concentrations of experimental samples. 
Statistical Analysis 
Using SSPS (Ver. 25.0; IBM Corp.; Armack, NY, USA), the results were analyzed in a 
one-way ANOVA test. This was used to determine significant differences between LAM dose 
responses. A post-hoc analysis using a two-sided Dunnett’s t-test was performed to identify 





The RAW 264.7 macrophages were treated with LAM and LPS over a 24-hour window 
and the nitrite concentration was measured with a Greiss assay. In the initial experiment, the 1.0 
ng/mL, 10 ng/mL, and 100 ng/mL LAM conditions did not exceed 5 μM nitrite and were not 
significantly different than the concentration of nitrite in the negative control (Fig. 4). The 1000 
ng/mL LAM response averaged 6.1 μM nitrite. The 100 ng/mL LPS positive control reached a 
nitrite concentration of 52.1 μM (Fig. 4). Significance occurred only in the LPS positive control 
and not in any LAM treatments (Appendix A). Given the low levels yielded by LAM treatment 
in experiment 1, an additional protocol was developed to include doses of higher concentrations. 
In experiment 2, the 1.0 ng/mL and 10 ng/mL treatments were replaced with 3000 ng/mL 
and 5000 ng/mL. The macrophages universally achieved increased output of NO as the nitrite 
concentration reached 12.9 μM in the 1000 ng/mL LAM dose. The 3000 ng/mL and 5000 ng/mL 
LAM treatments produced responses of 21.6 μM and 38.1 μM nitrite, respectively (Fig. 5). In 
this experiment, the positive control produced 72.7 μM nitrite in response to 100 ng/mL LPS. 
Only the 100 ng/mL LAM treatment was not significant when compared to the negative control 
(Appendix B). Two repetitions with the treatments 100-5000 ng/mL LAM showed similar 
responses. However, all conditions in experiment 3 yielded lower nitrite concentrations (Fig. 6). 
The results of the 100 ng/mL and 1000 ng/mL LAM doses were not statistically significant 
(Appendix C). The 3000 ng/mL and 5000 ng/mL LAM treatments, as well as 100 ng/mL LPS, 




Figure 4: Preliminary stimulation of RAW 264.7 murine macrophages with LAM derived from 
M. smegmatis. ​Initial dose response experiment measured by Greiss reaction used treatments of 
1.0-1000 ng/mL LAM (blue bars). Negative and positive controls were 0 ng/mL LAM and 100 
ng/mL LPS (orange bar), respectively. Absorbance recorded at 550 nm. The bars represent the ​± 
standard deviation among the four treatment wells. *P ​≤​ 0.05 in one-way ANOVA with 





Figure 5: Experiment 2 of RAW 264.7 murine macrophages stimulated with LAM derived from 
M. smegmatis. ​Dose response experiment measured by Greiss reaction used treatments of 
100-5000 ng/mL LAM (blue bars). Negative and positive controls were 0 ng/mL LAM and 100 
ng/mL LPS (orange bar), respectively. Absorbance recorded at 550 nm. The bars represent the ​± 
standard deviation among the four treatment wells. *P ​≤​ 0.05 in one-way ANOVA with 





Figure 6: Experiment 3 of RAW 264.7 murine macrophages stimulated with LAM derived from 
M. smegmatis. ​Dose response experiment measured by Greiss reaction used treatments of 
100-5000 ng/mL LAM (blue bars). Negative and positive controls were 0 ng/mL LAM and 100 
ng/mL LPS (orange bar), respectively. Absorbance recorded at 550 nm. The bars represent the ​± 
standard deviation among the four treatment wells. *P ​≤​ 0.05 in one-way ANOVA with 





The purpose of this study was to determine if RAW 264.7 murine macrophages would 
show dose-responsive activity when treated with LAM derived from ​M. smegmatis​. It was 
predicted that the interaction of LAM with the TLR-2 signaling pathway would increase NO 
output, and ultimately nitrite concentration, when dosed with increasing concentrations of LAM. 
The positive control of LPS from ​E. coli​ was used to determine if the magnitude of LAM 
response was comparable to a common standard. The results indicate that LAM can stimulate a 
dose-dependent, inflammatory response in murine macrophages. 
In a previous report, Zaman (2019) conducted two congruent trials similar to those in this 
study. Her preliminary experiment, compatible with experiment 1, showed significance at the 
100 ng/mL and 1000 ng/mL LAM doses, yielding approximately 8 μM and 55 μM nitrite 
respectively (Zaman 2019). There was also significance in the 100 ng/mL LPS control which 
produced approximately 104 μM (Zaman 2019). The second experiment performed by Zaman 
(2019) was identical to experiment 2 in this investigation, with the addition of 10 ng/mL and 
2000 ng/mL LAM treatments. A dose-response effect of LAM was observed between 1000 and 
5000 ng/mL and was determined to be significantly different from untreated controls (Zaman 
2019). Her data indicates a response of approximately 65 μM nitrite in the 5000 ng/mL LAM 
treatment, while the data from experiments 2 and 3 here show only 38.1 μM and 27.5 μM nitrite 
respectively. While similar trends exist between the two studies, the results of Zaman (2019) far 
exceeded the output of NO found in the data of this report. A potential explanation for these 
discrepancies could be the less than ideal growth conditions the RAW cells experienced due to 
damaged incubators. Despite the fact that this study yielded lower responses, the dose-response 
trends are analogous to those found by Zaman (2019) and show that LAM can induce 
dose-related NO production in RAW 264.7 murine macrophages. The results are in accordance 
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with other sources that indicate RAW cell stimulation with LAM can produce a NO response 
(Park et al. 2000). 
After analyzing the data of all three experiments, adjacent with those of Zaman (2019), it 
is evident that the RAW 264.7 murine macrophages are not as sensitive to LAM as they are LPS. 
There are several possibilities to explain this phenomenon, some of which refer to the different 
receptors through which each compound interacts with the macrophage. Since TLRs each bind 
with unique ligands, the difference could be a result of LPS interacting with TLR-4 and LAM 
with TLR-2. While it is difficult to find research on specific affinities of TLRs, it is likely that 
they fluctuate among the TLRs, potentially causing the response difference of LAM and LPS. 
The quantity of each TLR on the surface of the macrophage could also play a role in the level of 
response. If the presence of TLR-4 is far greater than that of TLR-2, it would be expected to see 
a diminished activation of the macrophages when treated with LAM. Additional research should 
be conducted in order to examine the effect of supplementary molecules on the NO production of 
macrophages. 
Limitations encountered when conducting this research included both local and global 
disruptions. Due to the halted and incomplete renovation of laboratory facilities, research that 
should have commenced in August of 2019, did not begin until January of 2020. At the end of 
February, the primary cell culture incubator suffered a thermostat malfunction, causing 
temperature regulation to fail. An alternative incubator was set up for use and the cells were 
transferred. This incubator, however, did not maintain proper humidity because of inconsistent 
CO​2​ regulation. Finally, March brought with it the news that classes would resume online after 
Spring break as a result of the COVID-19 outbreak. This prevented further experimentation 
which would have augmented the presented data. These protocols would have included using 
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ELISA for quantification of TNF-α and western blot analysis of iNOS. The original intentions of 
this study were to compare the relative NO output to the presence of both TNF-α and iNOS. If 
the research is to be continued, one could compare the TLR-4 and TLR-2 pathways, exploring 
the impact they have on the output of NO and pro-inflammatory cytokines. 
The results of the present study contribute on a small scale to the overall knowledge of 
interactions between LAM and macrophages. By knowing the extent at which LAM activates 
macrophage production of NO, scientists can begin to grasp the downstream effects of ​Mtb 
invasion. Research shows that pathogenic mycobacterial LAM acts as an intercalating agent that 
stunts phagosomal maturation (Guenin-Macé et al. 2009). Additionally, LAM from ​Mtb​ inhibits 
the production of pro-inflammatory cytokines, such as IL-12, preventing the development of 
other critical immune cells (Guenin-Macé et al. 2009). A thorough understanding of the 
molecular pathways of infection is vital for the improvement of TB treatments and medication. 
Given the continued severity and prevalence of the disease, the diagnosis and treatment of the 
disease has never been more crucial. Research in this field must continue in an attempt to more 
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Statistical analysis of experiment 1 and the data represented in Figure 4. One-way ANOVA with 
Dunnett’s host-hoc t-test analysis. Significance indicated when P ≤ 0.05. 
Oneway 
 




LAM Data  
 
Sum of Squares df Mean Square F Sig. 
Between Groups 7334.461 5 1466.892 252.152 .000 
Within Groups 104.715 18 5.817   
Total 7439.176 23    
Multiple Comparisons 
Dependent Variable:   LAM Data  
Dunnett t (2-sided)​a  
(I) V1 (J) V1 
Mean 
Difference (I-J) Std. Error Sig. 
95% Confidence Interval 
Lower Bound Upper Bound 
1 6 -.54750 1.70551 .997 -5.2571 4.1621 
2 6 -.77000 1.70551 .988 -5.4796 3.9396 
3 6 -1.22750 1.70551 .921 -5.9371 3.4821 
4 6 1.45500 1.70551 .860 -3.2546 6.1646 
5 6 46.63500​* 1.70551 .000 41.9254 51.3446 
*. The mean difference is significant at the 0.05 level. 







Statistical analysis of experiment 2 and the data represented in Figure 5. One-way ANOVA with 
Dunnett’s host-hoc t-test analysis. Significance indicated when P ≤ 0.05. 
Oneway 
 





LAM data  
 
Sum of Squares df Mean Square F Sig. 
Between Groups 14234.493 5 2846.899 1362.747 .000 
Within Groups 37.604 18 2.089   
Total 14272.097 23    
Multiple Comparisons 
Dependent Variable:   LAM data  
Dunnett t (2-sided)​a  
(I) V1 (J) V1 
Mean 
Difference (I-J) Std. Error Sig. 
95% Confidence Interval 
Lower Bound Upper Bound 
1 6 .41000 1.02203 .993 -2.4122 3.2322 
2 6 10.00000​* 1.02203 .000 7.1778 12.8222 
3 6 18.67500​* 1.02203 .000 15.8528 21.4972 
4 6 35.20250​* 1.02203 .000 32.3803 38.0247 
5 6 69.74750​* 1.02203 .000 66.9253 72.5697 
*. The mean difference is significant at the 0.05 level. 




Statistical analysis of experiment 3 and the data represented in Figure 6. One-way ANOVA with 
Dunnett’s host-hoc t-test analysis. Significance indicated when P ≤ 0.05. 
Oneway 
 




LAM/LPS μM Concentration  
 
Sum of Squares df Mean Square F Sig. 
Between Groups 13283.182 5 2656.636 1422.596 .000 
Within Groups 33.614 18 1.867   
Total 13316.796 23    
Multiple Comparisons 
Dependent Variable:   LAM/LPS μM Concentration  
Dunnett t (2-sided)​a  
(I) V1 (J) V1 
Mean 
Difference (I-J) Std. Error Sig. 
95% Confidence Interval 
Lower Bound Upper Bound 
1 6 .20000 .96630 1.000 -2.4683 2.8683 
2 6 1.47250 .96630 .433 -1.1958 4.1408 
3 6 8.45500​* .96630 .000 5.7867 11.1233 
4 6 26.47250​* .96630 .000 23.8042 29.1408 
5 6 65.43250​* .96630 .000 62.7642 68.1008 
*. The mean difference is significant at the 0.05 level. 
a. Dunnett t-tests treat one group as a control, and compare all other groups against it. 
